Quark Pharmaceuticals said this week that it has closed a $10 million round of private financing.
The company said it will use the funds to advance its RNAi drug pipeline, which includes the phase I acute renal failure treatment QPI 1002, which is also under phase I/II development for the prevention of delayed graft function; and QPI 1007, a phase I ocular neuroprotectant.